The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Managed to top up more at 1.60 earlier this week. This is a very long term hold for me. I like the way Eric manages the company and the vision he has. The pipeline has amazing potential and the range of collaborations is impressive. No debt and a good financial runway. I’d say there is about £3.5M cash if we include the grants.I wouldn’t be surprised if there was more news on that front and news from the US in the next 6 months.
Marmie
Yes great opportunity for those who got in at the bottom as I personally doubt we’ll see those numbers again. Also nice to see new faces and some diamond hands. There is a telegram group that it would be great if you joined, just go on Twitter, search #genf and you’ll find the link there :)
That’s 6 then! All feels rather exciting on no news and we are moving in the right direction. So many potential catalysts that could cause this share to explode. I would rather be out than in that’s for sure 👍
Five of us, bought some more today.
Four of us
HAPPY started building here the other week a long way of however big rewards to come
Hi guys,
Long time lurker just joined up, my favourite board of all my holds.
I have you to thank (or maybe not) for inspiring my accumulation of GENF.
Good luck
I have jumped on board following Swanny..😉
Three of us!!! :'-)))
Hey Porter, that makes two of us
GL
I deffo won’t be selling. Got companies like this being bought up for mega bucks. I’m here til buy out!
Can’t believe this isn’t at 2p now. No one interested in selling
A very nice 650k buy just in at 1.9p!!! Gla :-)
Very good past few days
News on patents, progress on pipeline, US investors, collaborators etc at anytime, but we're still awaiting Final reports from the 4 invivo studies to be officially published, which could be highly significant, although not sure if they're already in the mix as we progress to human clinical trials, or if there's going to be a peer-review or similar scientific publication, but Vera's podcast is well worth a listen as she goes into great depth of the studies they're carrying out on Sirt6, and interestingly enough, Vera hasn't published any news at all from her lab, so far this year???.Gla :-)
September 2023
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
........
A fascinating and insightful Podcast interview with Vera Gorbunova from 24/10/23 discussing the promising potential for Sirt6 and how she is conducting indepth research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)
SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1
Oct. 24, 2023
htTps://www.listennotes.com/podcasts/modern-healthspan/sirt6-the-science-behind-the-Z8u9qApmey_/
Not long now before sub 2p will be a distant memory with any luck, a major re-rate or two highly likely with plenty of significant positive newsflow stacking UP!!! Gla :-)
Yes not hard to have more cash at bank than the mcap!
Couldn't agree more Dave, ridiculously undervalued but our fortunes could change in a blink, and yes indeed Porter, along with the recent institutional investors, many pi's are appreciating the opportunity ahead. Final Results expected now which will outline prospects and potential and solid cash position , and more good news in the pipeline for full market appreciation and investor interest at anytime. Gla ....On and UP!!! :-)
Agree Dave, only bonus is it’s allowed us to passively load ready for when the market catches on :)
100% money. Good to see some new private investors jumping in at such a pivotal moment too!
TBF moneymunch, it's been ridiculous that we've been in the ones for so long.
A fair price here has to be around 5p and then see where it takes us.
Won't take much.
Thanks
Looking good and strong, very low free float with the majority of shares held for greater things to come and so any good news should see a solid and significant re-rate. Gla holders, Momentum building, Genflow is all set for a stellar year ahead imho. ;-)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers
23m
🧬 Genflow Biosciences has an updated presentation! 🧬
To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here: hTtps://loom.ly/qLRb1jE
#SIRT6 #GENF #NASH #aging #healthspan
Seems Eli Lilly are busy buying up readily established production plants for self administration injectables.
I would like to see SIRT6 being manufactured and available to the public to help boost their longevity via self injectables. It seems there are a diverse range of health benefits, not just for the liver!
https://www.biopharmadive.com/news/eli-lilly-nexus-manufacturing-factory-acquire/713897/
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers
18h
Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies.
It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/development stage, including treatments for diseases ranging Werner Syndrome to #NASH.
Learn more about Genflow's innovative studies & exciting investment thesis: https://lnkd.in/eYJ_AQ3H
#GENF #aging #healthspan #NASH #genetherapy
Investors – Genflow Bioscience